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Molecular basis of hereditary factor VII deficiency
in India: five novel mutations including a double
missense mutation (Ala191Glu; Trp364Cys) in 11
unrelated patients
We have studied the molecular basis of factor (F)
VII deficiency in 11 unrelated Indian patients.
Mutations were identified in all 11 and included 5
missense, 2 nonsense and a frame shift mutation.
Five of these were novel. These mutations were
considered to be causative of disease because of
their nature, evolutionary conservation and molec-
ular modeling. This is the first report of mutations
in patients with FVII deficiency from southern
India.Haematologica 2007; 92:1002-1003 
Factor VII (FVII) (OMIM: 227500) deficiency is a rare
(1:500,000) autosomal recessive disorder of blood coagula-
tion caused by heterogeneous mutations (~140) in FVII
gene.1 We describe the molecular abnormalities in the FVII
gene of south Indian patients with FVII deficiency and their
genotype-phenotype correlations.
The clinical and phenotypic data of the 11 unrelated
patients studied are detailed in Table 1. Genomic DNA was
screened for mutations in FVII gene by PCR (Table 2), con-
formation sensitive gel electrophoresis (CSGE)2 and DNA
sequencing (ABI 310 genetic analyzer, Applied Biosystems,
Foster city, CA, USA). The potential effects of missense sub-
stitutions were modeled by SwissPdb Viewer based on the
three-dimensional structure (PDB: 1dan) for the wild-type
FVII: tissue factor complex.3
We identified 8 different mutations and 6 (g.-323A1/A2,
g.-122T→C, g.73G→A, g.7880C→T, g.10523G→A,
g.10976G→A) previously reported polymorphisms1 in the
11 patients. The mutations included 5 missense, 2 nonsense
and 1 frame shift of which five were novel (Table 1). 
A novel p.Leu-55fs identified in two patients (33 and 114,
FVII: C <1%) predicts a premature termination codon (PTC)
at residue -15 in the propeptide region. This mutant protein
may not be generated due to nonsense-mediated decay of
the mRNA carrying the PTC. Similar null mutations (p.Leu-
52fs) resulting in the complete absence of FVII in plasma but
not incompatible with life have been previously described.4
Table 1. Clinical, hematologic and genetic data of patients with hereditary factor VII deficiency.
UPN AOIa/Sex Conb Sites FVII:Cc Residued Location Nucleotided Codon Aminoacid Domain Reported Restriction Haplotypeg
of bleeding change change Novele site alteredf
13 1/Male Yes Umbilical <1% 227 exon 8 10596 CAG→TAG Gln→X Catalytic Novel HhaI- A1A1-GG-GG-GG
stump (homozygous)
gastrointestinal,
dental extraction 
33 29/Male Yes Epistaxis, <1% -55 exon 1a 16delC Leu→fs Prepropeptide Novel StuI+ A1A1-GG-GG-GG
hemetemesis
46 33/Female No Epistaxis, 21% -1 exon 2 3820 CGC→TGC Arg→Cys Prepropeptide Novel AscI- A2A2-GG-GG-GG
menorrhagia (homozygous)
60 13/Female No Umbilical <1% 191 exon 7 9673 GCG→GAG Ala→Glu Activation Novel SacII- A1A1-GG-GG-GG
stump, epistaxis, (homozygous)
gastrointestinal,
hemarthroses, gingival
63 1/Male Yes Umbilical stump, <1% 382 exon 8 11061 CAG→TAG Gln→X Catalytic Novel NA A2A2-GG-GG-AA
epistaxis, gastrointestinal, (homozygous)
gingival, hemarthroses,
central nervous system  
101 16/Female No Gingival, <1% 227 exon 8 10596 CAG→TAG Gln→X Catalytic Novel HhaI- A1A1-GG-GG-GG
hemarthroses, (homozygous)
hematoma, dental extraction 
105 35/Female No Gingival, <1% 227 exon 8 10596 CAG→TAG Gln→X Catalytic Novel HhaI- A2A2-AA-GG-GG
hemarthroses (homozygous)
106 13/Female Yes Gingival, <1% 191 exon 7 9673 GCG→GAG Ala→Glu Activation Novel SacII- A2A2-GG-AA-AA
menorrhagia 364 exon 8 11009 TGG→TGC Trp→Cys Catalytic Reported Sau96I-
homozygous for
double mutation
114 11/Female No Gingival, <1% -55 exon 1a 16delC Leu→fs Prepropeptide Novel StuI+ A1A1-GG-GG-GG
hemarthroses,
umbilical stump bleeds
120 10/Male Yes Gingival, <1% 117 exon 5 7884 GGG→AGG Gly→Arg EGF2 Reported NA A2A2-AA-AA-AA
epistaxis (homozygous)
128 15/Female Yes Umbilical stump, <1% 152 exon 6 8961 CGA→CAA Arg→Gln Activation Reported NA A1A1-GG-GG-GG
epistaxis, gingival, (homozygous)
hemarthroses,
central nervous system  
aAge at first investigation; bconsanguinity status; cfactor VII coagulant (FVII: C) activity. dNucleotide and amino acid numbering according to O’Hara et al, 1987 10 and NCBI
nucleotide accession number J02933. eNovel mutations/polymorphisms, not reported previously in factor VII mutation database 1. f (+) sign indicates that a mutation creates a
restriction site; (-) indicates that the mutation abolishes a restriction site for the restriction enzyme; NA- restriction enzyme not available. gHaplotype construction based on
promoter -323 decanucleotide insertion (A2), no insertion (A1), intron 1a 73G→A, intron 7 10523G→A, exon 8 10976C→T (Arg353Gln) polymorphisms.
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A common founder for p.Leu-55fs is likely as both patients
had similar haplotype (Table1). A novel p.Arg-1Cys (Patient
46, FVII: C- 21%) occurs at a cleavage site (Arg-1 and Ala+1)
for a processing protease thereby disrupting the removal of
pre-prosequence from mature FVII during its biosynthesis.5
A novel p.Ala191Glu in activation domain was identified in
patients 60 and 106 (FVII: C<1%). Patient 106 had a second
homozygous mutation (p.Trp364Cys) that had been previ-
ously reported.1 The p.Ala191Glu and p.Trp364Cys muta-
tions identified in patient 106 were in a double heterozy-
gous state in her parents, confirming its double homozygos-
ity in the proband. Ala191 is a conserved (11 out of 13 relat-
ed serine proteases) hydrophobic amino acid buried in the
hydrophobic core involving Trp187, Val188, Val189,
Ser190Ala192, Cys194, and Phe195. Ala191 is close to
His193 that is a part of the active site catalytic triad (Asp242
and Ser344). His193 is partly exposed (accessibility 3) in this
hydrophobic stretch (Trp187-Phe195) of inaccessible (acces-
sibility 0) amino acids.6 The replacement of Ala191 by a
moderately hydrophilic Glu191 can surface expose this
residue and disturb the adjoining active site His193. Other
novel mutations detected in this study were nonsense
(p.Gln227X and p.Gln382X) mutations in catalytic domain
that result in PTCs. Of these, the p.Gln227X was identified
in three unrelated patients (13, 101, 105). Two of them (13
and 101) had a shared haplotype (Table1) and a common
founder is likely.
Previously reported approaches for FVII gene mutation
screening include denaturing gradient gel electrophoresis
(DGGE) and direct sequencing.7,8 Using our novel PCR-
CSGE strategy, 7 out of 8 disease causing mutations were
detected with a comparable sensitivity (88% vs. 91%) to
DGGE. DGGE requires GC clamped primers and optimiza-
tion of electrophoresis conditions for each of the PCR frag-
ments as opposed to the universal electrophoresis condi-
tions for CSGE. It is also possible to consider FVII gene
direct sequencing, but for reasons of cost and wide applica-
bility a simple mutation screening method such as CSGE
prior to sequencing provides a powerful tool for genetic
diagnosis. The genotype and phenotype relationship in FVII
deficiency is variable.7 A lack of correlation between in vitro
FVII: C and the clinical phenotype were noticed in some of
our patients. A mild-moderate phenotype (gum bleeding,
hemetemesis, Patient 33) contrasted with severe bleeding
symptoms (umbilical stump bleeds, hemarthroses, Patient
114) in spite of an identical p.Leu-55fs mutation. It would
be of interest to determine their thrombin generating poten-
tial, as small amounts of FVIIa are sufficient to initiate coag-
ulation and additional genetic or environmental factors may
play a role in modulating FVII levels.9 Of the 8 causative
mutations identified in this study, 3 (p.Leu-55fs,
p.Ala191Glu, p.Gln227X) were in 7 unrelated families.
Using haplotype analysis, we have shown that p.Leu-55fs
and p.Gln227X in two patients each had a common
founder. These data suggest that these common p.Leu-55fs,
p.Ala191Glu, p.Gln227X mutations could be first analyzed
by StuI, SacII and HhaI restriction fragment length polymor-
phism analysis for the genetic diagnosis of FVII deficiency in
the Indian population.
This is the first report describing mutations in FVII gene
from Southern India and the data show that mutations of
this gene in Indian patients are as heterogeneous as in other
populations. 
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Table 2. Primers used for amplification and sequencing of factor VII gene.
Exon Forward primer (5’-3’) Reverse primer (5’-3’) Region of FVII Amplicon size Annealing
gene amplified* (bp) temperature (°C)
Promoter+1a GCATGATTGCTATGGGACAA CTGCCCTTCCACCAAGTTTA g.-383 – g.108 491 58
1b GTGGGCTGTGAGGGACAGT GCAGGGAACACCCTCCTT g.1047-g.1328 282 58
2 GTGGGCCGTGGGGCGGTCTC GCCCCACGCGGCCTGGTTCA g.3699-g.4000 302 64
3+4 TGGTGTGTCCAGTGCTTACC CAATTTCCAACTGGGCTGAG g.5787-g.6211 425 58
5 CTTCCAGGCAGAACACCACT ATCCCACCTCACAATTGGTC g.7679-g.8066 388 58
6 CTCAGAGGATGGGTGTTTCTG TGCTAGGTGTGCTGACTTGG g.8810-g.9139 330 58
7 AGGGCGAGTCATCAGAGAAA AGTGGTACCCACCCAGCAC g.9538-g.9923 386 64
8A CTTGCCCCAGAAGGAGACT TCTCCCACCTTCCGTGACT g.10422-g.10873 452 58
8B CTGGAGCTCATGGTCCTCA TGCCCTCCTCTACCCCATTA g.10800-g.11240 441 58
*Nucleotide numbering according to O’Hara et al.10
